Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs

Cancer Science

Volumn 97, Issue 6, 2006, Pages 510-522

  Ooyama, Akio ^a   Takechi, Teiji ^a   Toda, Etsuko ^a   Nagase, Hideki ^a   Okayama, Yoshihiro ^a   Kitazato, Kenji ^a   Sugimoto, Yoshikazu ^a   Oka, Toshinori ^a   Fukushima, Masakazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL DERIVATIVE; IRINOTECAN; MESSENGER RNA; PACLITAXEL; UFT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION FUNCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREAS CARCINOMA; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UNINDEXED SEQUENCE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 33744539833     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00204.x     Document Type: Article

References (50)

1. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7.
2. Golub TR. Genome-wide views of cancer. N Engl J Med 2001; 8: 601-2.
3. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: Polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 12: 912-20.
4. Mayer F, Hartmann JT, von Pawel J et al. A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. Ann Oncol 2002; 5: 755-9.
5. Takahashi N, Suzuki H, Iwabuchi S, Yamazaki Y, Yanaga K. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: A case report. Hepatogastroenterology 2005; 61: 326-8.
6. Iwase H, Shimada M, Tsuzuki T et al. A phase II multicentric trial of S-1 combined with 24 h infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 2005; 25: 1297-301.
7. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996; 7: 137-49.
8. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972; 6: 1565-71.
9. Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 1992; 4: 265-9.
10. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 1999; 13: 17-21.
11. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 2002; 7: 288-323.
12. Fukushima M, Shimamoto Y, Kato T et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998; 9: 817-23.
13. Shirasaka T, Taguchi T. Preclinical and clinical practice of S-1 in Japan. In: Rustum YH, ed. Fluoropyrimidines in Cancer Therapy. Totowa, NJ: Humana Press, 2002; 285-302.
14. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.
15. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-20.
16. Shirao K, Ohtsu A, Takada H et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-61.
17. Saeki T, Takashima S, Sano M et al. A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004; 11: 194-202.
18. Furuse K, Kawahara M, Hasegawa K et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 2001; 5: 236-41.
19. Zembutsu H, Ohnishi Y, Tsunoda T et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62: 518-27.
20. Dan S, Tsunoda T, Kitahara O et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-47.
21. Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Letter 2004; 214: 19-33.
22. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001; 37: 1681-7.
23. Nukatsuka M, Fujioka A, Nakagawa F et al. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 2004; 25: 1531-6.
24. Takechi T, Okabe H, Ikeda K et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Report 2005; 14: 33-9.
25. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998; 77: 1-10.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
27. Takechi T, Okabe H, Fujioka A, Murakami Y, Fukushima M. Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 1998; 89: 1144-53.
28. Ikenaka K, Shirasaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353-9.
29. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42: 450-6.
30. Dan S, Shirakawa M, Mukai Y et al. Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci 2003; 94: 1074-82.
31. Kunz M, Moeller S, Koczan D et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 2003; 278: 45 651-60.
32. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-44.
33. Zhou Y, Gwadry FG, Reinhold WC. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects. Cancer Res 2002; 62: 1688-95.
34. Pusztai L, Sotiriou C, Buchholz TA. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: A molecular case study. Cancer Genet Cytogenet 2003; 141: 148-53.
35. De Lange R, Burtscher H, Jarsch M, Weidle UH. Identification of metastasis-associated genes by transcriptional profiling of metastatic versus non-metastatic colon cancer cell lines. Anticancer Res 2001; 21: 2329-39.
36. Ross DT, Scherf U, Eisen MB et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-35.
37. Tashiro T, Inaba M, Kobayashi T et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 1989; 24: 187-92.
38. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-55.
39. Takechi T, Fujioka A, Matsushima E, Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 2002; 38: 1271-7.
40. Fujiwara H, Terashima M, Irinoda T et al. Superior antitumor activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 2003; 39: 2387-94.
41. Usuki H, Ishimura K, Yachida S et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer 2003; 6: 66-70.
42. Massague J. Transforming growth factor-α. A model for membrane-anchored growth factors. J Biol Chem 1990; 15: 21 393-6.
43. De Luca A, Selvam MP, Sandomenico C et al. Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997; 73: 277-82.
44. Johnston PG, Lenz HJ, Leichman CG. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
45. Mariadason JM, Arango D, Shi Q et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63: 8791-812.
46. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004; 10: 4427-36.
47. Rechreche H, Mallo GV, Montalto G, Dagorn JC, Iovanna JL. Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer. Eur J Biochem 1997; 248: 225-30.
48. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95: 6355-60.
49. Lin MT, Chang CC, Chen ST et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-κB-dependent XIAP up-regulation. J Biol Chem 2004; 279: 24 015-23.
50. Villalona-Calero MA, Weiss GR, Burris HA et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999; 17: 1915-25.